Cochrane review finds mifepristone more effective than other emergency contraception pills

A Cochrane systematic review of 87 randomized controlled trials involving approximately 36,000 women of reproductive age found that emergency contraception containing mifepristone prevented more pregnancies and produced fewer overall side effects than levonorgestrel, while also outperforming the Yuzpe regimen. The analysis, led by researchers from Oregon Health & Science University, rated the evidence for low-dose mifepristone as high certainty. The review was published in the Cochrane Database of Systematic Reviews.

The pooled evidence showed that low-dose mifepristone, defined in the review as less than 25 mg, reduced the relative risk of pregnancy by 27% compared with levonorgestrel, a progestin-only emergency contraceptive sold under names including Plan B and Next Choice. Mid-dose mifepristone, corresponding to 25–50 mg, also prevented more pregnancies and was associated with fewer overall side effects than levonorgestrel. Mifepristone produced a still larger advantage over the Yuzpe regimen, which combines estrogen and progestin, by substantially reducing pregnancy risk and sharply lowering the rates of nausea and vomiting. In contrast, only two included trials compared mifepristone with copper intrauterine devices, leaving too little evidence for firm conclusions about their relative effectiveness.

Mifepristone is an antiprogestin that acts differently from steroid hormone-based emergency contraceptive methods such as levonorgestrel and the combined Yuzpe regimen. According to lead author Dr Shaalini Ramanadhan, this different mechanism can delay or block ovulation and helps explain the medication’s distinct side-effect profile. The principal trade-off identified across nearly all comparisons was a higher likelihood of delayed menstruation among people who received mifepristone. Because a delayed period could be interpreted as treatment failure or pregnancy, the authors noted that this effect may cause stress or anxiety. Where treatment satisfaction was reported, however, it was equal to or higher for mifepristone than for the alternative methods examined.

The findings come from a systematic review rather than a new clinical trial, and the evidence base was geographically uneven: 79 of the 87 randomized trials were conducted in China, with the remaining studies from the United Kingdom, Cuba, and multinational settings. The review compared several interventions, but its strongest comparative findings concerned mifepristone doses used for emergency contraception, not the much higher doses commonly approved for medical termination of early pregnancy. The limited number of trials involving copper intrauterine devices also means that the review could not establish whether mifepristone was more effective than that method. Satisfaction and side-effect results were available only where individual studies reported them, and the review’s scope concerned reproductive-age women; it did not evaluate the use of mifepristone as a routine contraceptive or for other conditions such as fibroids, abnormal bleeding, or breast cancer.

Despite the high-certainty evidence favoring mifepristone over the commonly used levonorgestrel pill, access remains restricted in some countries. Mifepristone is widely associated with abortion and therefore faces political scrutiny, legal restrictions, and targeted bans in various jurisdictions. In some countries, authorities have approved higher doses, typically 200 mg, in combination with misoprostol for medical termination of early pregnancy, rather than for emergency contraception. Ramanadhan said that recognizing mifepristone’s additional use as emergency contraception could help expand access and familiarity with the medicine. The review establishes comparative performance within the evidence studied, but it does not itself change regulatory approval, clinical guidelines, or product availability.

Subject of Research: Comparative effectiveness of mifepristone and other emergency contraception methods in reproductive-age women

Article Title: Mifepristone more effective than other common emergency contraception methods

Article References: Mifepristone more effective than other common emergency contraception methods. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: mifepristone, emergency contraception, pregnancy prevention, levonorgestrel, Yuzpe regimen, copper intrauterine devices, Cochrane review, randomized controlled trials, side effects, ovulation, effective, than